Add-on naltrexone/bupropion helps shed pounds in patients on incretins
27 Jul 2021
The extended-release fixed-dose combination of naltrexone and bupropion (NB) appears to induce weight loss in obese or overweight patients with type 2 diabetes mellitus (T2DM) receiving treatment with dipeptidyl peptidase 4 inhibitors (DPP-4is) or glucagon-like peptide-1 receptor agonists (GLP1-RAs), according to a post-hoc analysis of the LIGHT trial.
Antigen rapid tests: Moving toward more efficient COVID-19 testing
01 Jul 2021;
At the time of writing, there have been 175,306,598 confirmed infections and 3,792,777 deaths attributed to the COVID-19 pandemic globally. [https://covid19.who.int/, accessed 14 June 2021] Real-time reverse transcription polymerase chain reaction (RT-PCR) has been instrumental in detecting the infection and preventing more widespread transmission of the disease.